DC-CIK过继细胞免疫治疗原发性肝癌的研究进展

【摘要】〓原发性肝癌(以下简称肝癌)临床往往较难早期发现,确诊时往往病情已进入中、晚期,病死率高。目前肝癌的治疗主要是以手术切除、肝移植、局部消融、化学治疗栓塞及其他局部区域治疗、分子靶向治疗等,但这些方法的治疗效果并不理想,患者5年存活率仍然较低。目前细胞免疫治疗现在得到了越来越多的重视,采用树突状细胞(DC)联合细胞因子诱导的杀伤细胞(cytokine induced killer, CIK)的细胞免疫治疗是其中方法之一。DC和CIK细胞是恶性肿瘤免疫治疗的两个重要因素,两者之间的相互作用及所诱发的免疫应答是免疫治疗的重要部分。现就DC-CIK过继细胞治疗原发性肝癌的研究进展予以综述。

Progresses in DC-CIK adoptive cellular immunotherapy in treatment of hepatoceHular carcinoma

Hepatocellular carcinoma （HCC） is the most common malignant tumor in China. HCC is difficult to find and confirm in early stage. Most of patients were in advanced stage when the symptom or signs were presented.The various treatments of HCC, such as liver resection, transplantation, local ablation, chemotherapy, and molecular targeted therapy, have not improved the 5-years survival rate efficiently. Cell-based therapies is now gaining more and more attention since some success have been achieved, and DC combined CIK ceils therapy is one of these attempts. DC and CIK cells are two important factors for cancer immunotherapy. The interaction between them and induced immune response are important parts of the treatment. The advance of DC-CIK cell therapy for HCC is reviewed in this paper.